Search results for "CNS"

showing 10 items of 74 documents

Sindrome di di Crigler-Najjar tipo 2: due nuove mutazioni missense nel gene UGT1A1.

2009

La sindrome di Crigler-Najjar (CNS) è una malattia molto rara (prevalenza 1/1.000.000 nati) a trasmissione autosomica recessiva, caratterizzata da un incremento cronico e grave di bilirubina sierica indiretta (non coniugata), dovuta alla parziale (tipo 2) o completa (tipo 1) assenza funzionale dell’enzima epatico glucoronosil transferasi UGT1. La malattia si manifesta in età neonatale con un ittero precoce e intenso, dovuto alla presenza di bilirubina non coniugata e l'esame fisico è nella norma; in epoca di sviluppo gli effetti clinici della CNS tipo 1 sono letali in quanto l’eccesso di bilirubina porta inevitabilmente ad una encefalopatia essendo tale pigmento fortemente liposolubile. Le …

Settore MED/38 - Pediatria Generale E SpecialisticaCrigler-Najjar (CNS) gene UGT1A1 NUOVA VARIANTE.
researchProduct

Malformations of central nervous system: General issues

2013

Malformations of the central nervous system (CNS) encompass a heterogeneous group of congenital anomalies that may be isolated or appear as part of a genetic syndrome. Advances in identifying the genetic etiology underlying many CNS malformation and syndromes have led to the current genetic-based classifications that allows us to better estimate prognosis and potential complications. Herein, we discuss the main genetic, clinical and radiological features and their implications for diagnostic testing and disease management

Settore MED/38 - Pediatria Generale E SpecialisticaSettore MED/31 - OtorinolaringoiatriaCNS malformations genetic investigations developmental delay.
researchProduct

Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.

2023

Background and ObjectivesRelapsing-remitting multiple sclerosis (RRMS), aquaporin-4 antibody–positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) may have overlapping clinical features. There is an unmet need for imaging markers that differentiate between them when serologic testing is unavailable or ambiguous. We assessed whether imaging characteristics typical of MS discriminate RRMS from AQP4-NMOSD and MOGAD, alone and in combination.MethodsAdult, nonacute patients with RRMS, APQ4-NMOSD, and MOGAD and healthy controls were prospectively recruited at the National Hospital for Neurology and Neurosurgery (L…

Sistema nerviós central - MalaltiesMalalties autoimmunitàries:aminoácidos péptidos y proteínas::proteínas::glicoproteínas::glicoproteínas de membranas::butirofilinas::glicoproteína mielínica del oligodendrocito [COMPUESTOS QUÍMICOS Y DROGAS]:Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases CNS::Myelitis Transverse::Neuromyelitis Optica [DISEASES]:enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::mielitis transversa::neuromielitis óptica [ENFERMEDADES]:Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases CNS::Multiple Sclerosis [DISEASES]Esclerosi múltiple:Amino Acids Peptides and Proteins::Proteins::Glycoproteins::Membrane Glycoproteins::Butyrophilins::Myelin-Oligodendrocyte Glycoprotein [CHEMICALS AND DRUGS]:Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Tomography::Magnetic Resonance Imaging [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]:enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES]Imatgeria per ressonància magnèticaNA:diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::tomografía::imagen por resonancia magnética [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Neurology (clinical)Neurology
researchProduct

Triiodothyronine accelerates the synthesis of synapsin I in developing neurons from fetal rat brain cultured in a synthetic medium.

1990

The effect of Triiodothyronine (T3) on Synapsin I appearance in rat cortical neurons has been investigated in vitro. Neuronal cultures from 16-day-old fetal rat brain grown in the absence of T3, express immunohystochemically detectable Synapsin I at the 14th day in vitro. The addition of the hormone to the culture medium determines an early (at the 7th day in vitro) appearance of fluorescent dots specific for Synapsin I. © 1990 Plenum Publishing Corporation.

Synapsin Imedicine.medical_specialtyCNS developmentCentral nervous systemFluorescent Antibody TechniqueNerve Tissue ProteinsBiologySettore BIO/19 - Microbiologia GeneraleBiochemistryCellular and Molecular NeuroscienceFetusInternal medicinemedicineAnimalschemically defined mediumimmunofluorescenceCells CulturedNeuronsFetusTriiodothyronineNeuroscience (all)BrainGeneral MedicineSynapsinsIn vitroCulture MediaRatsChemically defined mediummedicine.anatomical_structureEndocrinologynervous systemneuronal cultureCerebral cortexCell cultureTriiodothyronineSettore MED/26 - NeurologiaSynapsin 1Neurochemical research
researchProduct

Poliprenolu efekti uz Wistar līnijas žurku telpisko atmiņu stresa modelī

2016

Poliprenoli (PP) ir vitāli svarīgi komponenti dzīvo organismu šūnās, tiem piemīt hepatoprotektīva, pretvīrusa, imūnmodulējoša un holesterīna pazeminoša iedarbība (Vais et al., 2012; Safatov et al., 2000; Pronin et al., 2013;). Ir maz pētīts par to ietekmi uz CNS funkcijām, atsevišķi dati liecina ka PP uzlabo kognitīvās funkcijas Alcheimera slimības (AD) žurku modelī (Fedotova et al., 2010; Wang et al., 2014). PP piemīt arī antioksidatīvā iedarbība (Bizzarri et al., 2003) , tāpēc tas liek domāt, ka PP var pasargāt no stresa negatīvās ietekmes uz kognitīvām funkcijām. Darba mērķis bija izvērtēt PP iedarbību per se un akūta stresa ietekmē uz izmēģīnājuma dzīvniekiem (Wistar līnijas žurkām) atm…

atmiņapoliprenolistressFarmācijaCNS
researchProduct

Zentral dämpfende Wirkstoffe, 7. Mitt. Kernsubstituierte (Diallylamino)-1,3,5-triazine

1988

Aus der Umsetzung von 2,4-Dichlor-6-(diallylamino)-1,3,5-triazin (1) mit langkettigen primaren (2a-b) und cyclischen sekundaren (2c-f) Aminen gehen die kernsubstituierten Chlor-diallylamino-1,3,5-triazine (3a-f) hervor. Ein fur Strukturtyp 3 charakteristischer ms Fragmentierungsweg beinhaltet die Umbildung der Diallylaminogruppe zum Aziridinring. Unter den neu entwickelten Verbindungen findet sich zentral dampfende Wirksamkeit besonders in 3a ausgepragt. Daruber hinaus weist Strukturtyp 3 Antiprotozoen-, anthelminthische und insektenwachstumsregulatorische Wirkung auf. CNS Depressants, VII: (Diallylamino)-1,3,5-triazines Substituted at the Triazine Nucleus The reaction of 2,4-dichloro-6-(di…

chemistry.chemical_compoundchemistryStereochemistryCns depressantDrug DiscoveryPharmaceutical ScienceCns depressantsAziridineMass spectrometricTriazineArchiv der Pharmazie
researchProduct

Effect of extracellular vesicles from CSF of multiple sclerosis patients and healthy controls on astrocytes in culture

2017

INTRODUCTION Secretion of extracellular vesicles (EVs) and EV-mediated exchange of molecules among brain cells, under physiological conditions, has been described years ago. At the same time, ability of EVs to transfer proteins and nucleic acids to the surrounding cells, thus modifying their phenotypes, has been clearly demonstrated for tumor cells of different origins, including brain cancers. More recently, involvement of EVs in pathological processes affecting the Central Nervous System (CNS), and their capacity of transferring damaging cargoes have been also suggested. To explore these functions, we exposed primary cultures of astrocytes to EVs isolated from cerebral spinal fluid (CSF) …

extracellular vesicles (EVs) Central Nervous System (CNS) primary cultures of astrocytes multiple sclerosis (MS)Settore BIO/10 - BiochimicaSettore MED/26 - NeurologiaSettore BIO/06 - Anatomia Comparata E Citologia
researchProduct

Komercnoslēpuma aizsardzība un tā ietekme uz personas tiesībām iegūt informāciju

2018

Eiropas Savienības dalībvalstu atšķirīgais normatīvais regulējums komercnoslēpuma aizsardzībā un 2016. gadā pieņemtā Komercnoslēpuma aizsardzības dirketīva ir raisījusi plašas diskusijas šo tiesību ietekmē uz sabiedrības tiesībāms uz informāciju. Tādēļ darbā tiek izpētīts un izanalizēts tiesību uz informāciju nozīmīgumus demokrātiskā sabiedrībā, nonākot līdz šo tiesību būtības un piemērošanas jomu noskaidrošanai. Tāpat tiek vērtēta un analizēta komercnoslēpuma aizsardzības būtība un tvērums. Tiek izvērtēti un salīdzināti gan ECT, gan EST, Eiropas valstu un ASV normatīvais regulējumus un tiesu spriedumi, kā arī tiek apskatīti dažādi tiesībzinātnieku viedokļi, lai noskaidrotu galvenos problēm…

komercnsolēpumskomercnoslēpuma aizsardzībatiesības uz vārda brīvībutiesības uz informācijuinformācijas atklātībaJuridiskā zinātne
researchProduct

Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosus

2021

Background: The aim was to evaluate the diagnostic potential of serum neurofilament light chain (sNfL) measurements in patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Methods: sNfL levels were determined by single molecule array assay in a retrospective cross-sectional cohort of 144 patients with systemic lupus erythematosus (SLE). After log-transformation of sNfL levels, mean sNfL levels were compared between NPSLE patients and SLE patients without neuropsychiatric disease using Student’s t test. Furthermore, the association of different neuropsychiatric manifestations with sNfL levels was assessed using a one-way analysis of variance (ANOVA) with post hoc analysis. As…

medicine.medical_specialtyNeurofilament lightCentral nervous systemGastroenterologychemistry.chemical_compoundInternal medicinePost-hoc analysismedicineRC346-429Original ResearchPharmacologyCreatininebusiness.industrymedicine.anatomical_structureneurofilament light chainNeurologychemistryCohortBiomarker (medicine)biomarkerMultiple linear regression analysisNeurology (clinical)Neurology. Diseases of the nervous systemCNSbusinessNeuropsychiatric diseaseneurolupusNPSLETherapeutic Advances in Neurological Disorders
researchProduct

Recommendations for the clinical use of somatosensory-evoked potentials

2008

The International Federation of Clinical Neurophysiology (IFCN) is in the process of updating its Recommendations for clinical practice published in 1999. These new recommendations dedicated to somatosensory-evoked potentials (SEPs) update the methodological aspects and general clinical applications of standard SEPs, and introduce new sections dedicated to the anatomical-functional organization of the somatosensory system and to special clinical applications, such as intraoperative monitoring, recordings in the intensive care unit, pain-related evoked potentials, and trigeminal and pudendal SEPs. Standard SEPs have gained an established role in the health system, and the special clinical ap…

medicine.medical_specialtySpinothalamic TractsHealth Planning GuidelinesLaser-Evoked Potentialsintraoperative monitoringMEDLINEcomaElectroencephalographysomatosensory-evoked potentialsClinical neurophysiologyEvoked Potentials SomatosensoryPhysiology (medical)Intensive carelaser-evoked potentialsHumansMedicinepainMedical physicspain-evoked potentialsEvoked potentialcns disease; coma; intensive care; intraoperative monitoring; laser-evoked potentials; pain; pain-evoked potentials; pudendal-evoked potentials; recommendations; somatosensory-evoked potentials; trigeminal-evoked potentialsintensive carecns diseasemedicine.diagnostic_testbusiness.industrytrigeminal-evoked potentialsElectroencephalographyNeurophysiologyElectric StimulationSensory Systemspudendal-evoked potentialsNeurologySomatosensory evoked potentialrecommendationsNeurology (clinical)Nervous System DiseasesbusinessNeuroscienceClinical Neurophysiology
researchProduct